About Acoramidis API
Therapeutic CategoryCardiology
CAS Number
1446711‑81‑4
API Technology
Small‑molecule synthetic API
Dose Form
Tablets
Dr Reddy's Development Status
Under Development
Mechanism of action
Acoramidis selectively binds to transthyretin (TTR) at the thyroxine‑binding sites.
Stabilizes the TTR tetramer, preventing dissociation into misfolded monomers.
This inhibition prevents amyloid fibril formation and cardiac amyloid deposition.
Demonstrates >90% TTR stabilization across wild‑type and variant TTR genotypes.
Indication
Indicated to reduce cardiovascular death and cardiovascular‑related hospitalization in adult patients with:
Wild‑type or variant transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM)
Related APIs
Acoramidis
Cardiology
Aficamten
Cardiology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.